Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment crawled time : 08:00 save search
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $48.99 -0.31% 0.84% 7.1M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
Published: 2024-03-22 (Crawled : 08:00) - biospace.com/
BPTS | $9.82 -15.37% -24.77% 9.1K
|
Manufacturing
|
| O: -8.72%
H: 13.47%
C: 6.08%
treatment
Water Treatment Equipment Market size in Power Industry to grow by USD 1.34 billion from 2022 to 2027, Increasing power demand to drive the growth, Technavio
Published: 2024-03-15 (Crawled : 08:00) - prnewswire.com
XYL | News | $130.72 1.35% -0.02% 950K
|
Producer Manufacturing
|
| O: -0.91%
H: 1.14%
C: 0.37%
ECL | News | $219.66 0.16% 0.51% 720K
|
Process Industries
|
| O: -0.98%
H: 2.03%
C: 1.83%
water treatment market
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Published: 2024-03-06 (Crawled : 08:00) - globenewswire.com
BMEA | $10.98 1.39% 1.28% 690K
|
Professional, Scientific, and T...
|
| O: -16.72%
H: 16.45%
C: 8.29%
alent-111 pancreatic treatment therapy
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
lung drug cancer treatment application therapeutics
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
Published: 2024-02-13 (Crawled : 08:00) - globenewswire.com
VRTX | $404.91 1.25% 1.43% 730K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
CRSP | News M | $56.41 1.35% 1.42% 1.1M
|
Health Technology
|
| O: -5.3%
H: 3.85%
C: 0.54%
first disease cell treatment
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
LEGN | News | $47.45 0.83% 0.76% 1.8M
|
Health Technology
|
| O: 0.78%
H: 3.23%
C: 2.76%
carvykti life treatment study
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.99 -0.31% 0.84% 7.1M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
treatment lymphomas potential
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.99 -0.31% 0.84% 7.1M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
unique treatment
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
BMY | $48.99 -0.31% 0.84% 7.1M
|
Health Technology
|
| O: 0.42%
H: 1.23%
C: 1.13%
breyanzi treatment leukemia
Medical Aesthetics Market 2023-2027 | The increased emphasis on fat-loss treatments is the market trend- Technavio
Published: 2023-11-03 (Crawled : 08:00) - prnewswire.com
ANIK | $25.79 -0.62% -0.72% 36K
|
Health Technology
|
| O: 27.49%
H: 0.17%
C: -12.76%
medical market
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
Published: 2023-10-27 (Crawled : 08:00) - biospace.com/
CALT | $18.2 0.65% -1.71% 1.7K
|
Health Technology
|
| O: 2.58%
H: 0.08%
C: -3.42%
nefecon nephropathy drug approval treatment application
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-10-04 (Crawled : 08:00) - biospace.com/
TEVA | $13.01 1.01% -0.62% 8.1M
|
Health Technology
|
| O: 1.46%
H: 0.21%
C: -5.65%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
disease treatment collaboration teva sanofi
Female Sexual Dysfunction Treatment Market to grow by USD 7.76 billion from 2022-2027; North America to account for 61% of market growth - Technavio
Published: 2023-09-11 (Crawled : 08:00) - prnewswire.com
ENDPQ | News | $0.0007 -50.0% 1K
|
n/a
|
| O: 0.0%
H: 10.0%
C: 0.0%
VTRS | News A | $11.36 0.98% 0.97% 3.9M
|
Health Technology
|
| O: 0.4%
H: 0.69%
C: -1.38%
america treatment growth market
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression
Published: 2023-09-06 (Crawled : 08:00) - compasspathways.com
CMPS | $8.25 -1.32% -1.52% 360K
|
Health Technology
|
| O: 0.89%
H: 5.29%
C: 3.86%
comp360 depression publication treatment potential psilocybin study
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC
Published: 2023-09-01 (Crawled : 08:00) - prnewswire.com
IGMS | $7.7 14.07% 12.68% 380K
|
Health Technology
|
| O: 0.56%
H: 3.76%
C: -3.06%
unique treatment
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine
Published: 2023-07-25 (Crawled : 08:00) - globenewswire.com
CMPS | $8.25 -1.32% -1.52% 360K
|
Health Technology
|
| O: -0.8%
H: 2.19%
C: -0.35%
treatment psilocybin results study
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology
Published: 2023-07-17 (Crawled : 08:00) - globenewswire.com
CMPS | $8.25 -1.32% -1.52% 360K
|
Health Technology
|
| O: 3.47%
H: 0.0%
C: -2.87%
comp360 positive depression publication trial psilocybin
Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause
Published: 2023-06-28 (Crawled : 08:00) - biospace.com/
ALPMY | News | $9.49 -0.42% -1.11% 480K
|
Manufacturing
|
| O: 1.2%
H: 0.26%
C: -0.2%
positive treatment topline trial results
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
Published: 2023-05-16 (Crawled : 08:00) - prnewswire.com
IFRX | $1.36 -0.73% 0.0% 97K
|
Health Technology
|
| O: 2.69%
H: 1.61%
C: -1.61%
covid-19 partnership treatment gohibic
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.